Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Alkermes PLC said it is selling its Georgia manufacturing facility and global rights to its experimental pain treatment to Recro Pharma Inc., as the Irish specialty-pharmaceutical company seeks to focus on its pipeline of central-nervous-system treatments. Alkermes said it will receive a $50 million initial payment and up to $120 million in milestone payments.
READ FULL ARTICLE
From The Wall Street Journal
Please login or register first to view this content.
Enjoying our content?
Thanks for visiting Clinical Pain Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Clinical Pain Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Please login or register first to view this content.